Texas-based Pulmotect, which is developing an inhaled immune stimulant for the treatment of respiratory diseases, has announced the appointment of Colin Broom as CEO. Broom was most recently CEO of Nabriva Therapeutics and previously served as Chief Scientific Officer at ViroPharma and in various roles at Amgen, Aventis, and GSK.
Pulmotect is a spin out of Fannin Innovation Studio, which licenses research from the University of Texas MD Anderson Cancer Center and Texas A&M University and creates companies to commercialize the technology. In April 2018, Pulmotect announced that it had raised $12 million in Series B financing for continued clinical development of its PUL-042 inhaled immune stimulant.
Fannin Executive chair Leo Linbeck III said, “Attracting such a highly-regarded and proven CEO as Colin is a clear signal of the power and potential of Pulmotect’s development program. Under his leadership, I’m confident that we will advance our technology further into the clinic and closer to the marketplace. His addition is a real game-changer for the company.”
Broom commented, “I am delighted to be joining Pulmotect at such an exciting time in the company’s history. The potential of their technology is tremendous and presents an opportunity to develop a new therapeutic approach that could positively impact many patients. I look forward to working with the team and our key collaborators and experts to help move the program ahead. Our priority is to advance PUL-42 into Phase 2 and 3 trials as soon as possible with an initial focus on immunocompromised patients who are at high risk of respiratory complications from bacterial, viral or fungal causes.”
Read the Fannin Innovation Studio press release.
